Evidence map›Paper›PMID 38795733›Full record

ArticleThe Journal of allergy and clinical immunology2024

Oral mucosa effectively protects against peanut allergy in mice.

Yuya Yoshida, Koji Iijima, Mayumi Matsunaga, Mia Y Masuda, Min-Jhen Jheng, Takao Kobayashi, Hirohito Kita

Abstract read
In one paragraph

Article in The Journal of allergy and clinical immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuya YoshidaDivision of Allergy, Asthma and Clinical Immunology, and Department of Medicine, Mayo Clinic Arizona, Scottsdale, Ariz; Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata, Osaka, Japan.
Koji IijimaDivision of Allergy, Asthma and Clinical Immunology, and Department of Medicine, Mayo Clinic Arizona, Scottsdale, Ariz.
Mayumi MatsunagaDivision of Allergy, Asthma and Clinical Immunology, and Department of Medicine, Mayo Clinic Arizona, Scottsdale, Ariz.
Mia Y MasudaImmunology Program, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minn and Scottsdale, Ariz.
Min-Jhen JhengVirology and Gene Therapy Program, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minn and Scottsdale, Ariz.
Takao KobayashiDivision of Allergy, Asthma and Clinical Immunology, and Department of Medicine, Mayo Clinic Arizona, Scottsdale, Ariz.
Hirohito KitaDivision of Allergy, Asthma and Clinical Immunology, and Department of Medicine, Mayo Clinic Arizona, Scottsdale, Ariz; Department of Immunology, Mayo Clinic Rochester, Rochester, Minn. Electronic address: kita.hirohito@mayo.edu.

Funding

Mechanisms of Allergen-induced Type 2 ImmunityR37AI071106 · NIAID · MAYO CLINIC ROCHESTER · PI Hirohito Kita · 2018 to 2026
$5.2M
NIAID NIH HHS R37 AI071106
6 · The paper itself

Abstract

backgroundOral consumption of peanut products early in life reduces the incidence of peanut allergy in children. However, little is known about whether exposure via the oral mucosa alone is sufficient or whether the gastrointestinal tract must be engaged to protect against peanut allergy.

objectiveWe used a mouse model and examined the effects of peanut allergen administration to only the oral cavity on allergy development induced by environmental exposure.

methodsNaive BALB/c mice were administered peanut flour (PNF) sublingually, followed by epicutaneous exposure to PNF to mimic a human condition. The sublingual volume was adjusted to engage only the oral cavity and prevent it from reaching the esophagus or gastrointestinal tract. The efficacy was evaluated by examining the anaphylactic response, antibody titers, and T follicular helper cells.

resultsThe mice exposed epicutaneously to PNF developed peanut allergy, as demonstrated by increased plasma levels of peanut-specific IgE and the manifestation of acute systemic anaphylaxis following intraperitoneal challenge with peanut extract. The development of peanut allergy was suppressed when mice had been given PNF sublingually before epicutaneous exposure. There were fewer T follicular helper cells in the skin-draining lymph nodes of mice that received sublingual PNF than in the mice that received PBS. Suppression of IgE production was observed with sublingual PNF at 1/10 of the intragastric PNF dose.

conclusionAdministration of peanut allergens only to the oral cavity effectively prevents the development of peanut allergy. The capacity of the oral mucosa to promote immunologic tolerance needs to be evaluated further to prevent food allergy.

Indexed as

AllergensArachisImmunoglobulin EMice, Inbred BALB CMouth MucosaPeanut HypersensitivityAdministration, SublingualAnaphylaxisAnimalsDisease Models, AnimalFemaleHumansMiceT Follicular Helper CellsAllergensImmunoglobulin Eanaphylaxisepicutaneous exposureIgEPeanut allergysublingual administrationT(FH) cells

Identifiers

PMID38795733
PMCPMC11456774

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.